{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:03:59Z","timestamp":1792119839130,"version":"4.4.0"},"reference-count":0,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2005,1,19]],"date-time":"2005-01-19T00:00:00Z","timestamp":1106092800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:p>This prospective, multicentre study was conducted during 2\u201330 April 2001 in the internal medicine\/infectious diseases services in France and included data from 1858 hepatitis C virus (HCV)-infected patients, half of whom were HIV co-infected. The aims were to outline the type of pre-therapeutic evaluation of HCV infection performed (HCV RNA, genotype, liver biopsy); determine the proportion and characteristics of patients receiving antiviral treatment; and determine if any changes in these parameters had occurred between 1995 and 2001. Patients whom had a complete pre-therapeutic evaluation (39%, 709\/1834) and received antiviral treatment (38%, 690\/1830) were more likely to have abnormal liver biochemistry, cirrhosis and cryoglobulinaemia (<jats:italic>P<\/jats:italic>&lt;0\u00b7001). Injecting drug users and HIV-co-infected patients were less likely to have a complete pre-therapeutic evaluation or receive antiviral treatment (<jats:italic>P<\/jats:italic>&lt;0\u00b7001). A complete pre-therapeutic evaluation was more often performed in 2001 than in 1995 (39% <jats:italic>vs<\/jats:italic>. 6%, <jats:italic>P<\/jats:italic>&lt;0\u00b7001), including qualitative HCV RNA testing (91% <jats:italic>vs<\/jats:italic>. 68%, <jats:italic>P<\/jats:italic>&lt;0\u00b7001), genotyping (59% <jats:italic>vs<\/jats:italic>. 7%, <jats:italic>P<\/jats:italic>&lt;0\u00b7001) and a liver biopsy (60% <jats:italic>vs<\/jats:italic>. 29%, <jats:italic>P<\/jats:italic>&lt;0\u00b7001). The frequency of anti-HCV treatment approximately doubled between 1995 and 2001 (20% <jats:italic>vs<\/jats:italic>. 38%, <jats:italic>P<\/jats:italic>&lt;0\u00b7001). Although adherence to consensus recommendations regarding pre-therapeutic evaluation is not ideal, a substantial improvement has occurred since 1995. Nevertheless, means of increasing the availability of antiviral therapies, particularly for patients with HIV co-infection or injecting drug use, require further study.<\/jats:p>","DOI":"10.1017\/s0950268804003486","type":"journal-article","created":{"date-parts":[[2005,3,2]],"date-time":"2005-03-02T15:56:40Z","timestamp":1109779000000},"page":"305-314","source":"Crossref","is-referenced-by-count":8,"title":["Management of chronic hepatitis C in French departments of internal medicine and infectious diseases"],"prefix":"10.1017","volume":"133","author":[{"given":"P.","family":"CACOUB","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"GODEREL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"MORLAT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"SENE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. P.","family":"MYERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"ALRIC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"LOUSTAUD-RATTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"MELIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"LIMAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"OUZAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"PERRONNE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"CARRAT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2005,1,19]]},"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268804003486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T19:39:24Z","timestamp":1554579564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268804003486\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,19]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0950268804003486"],"URL":"https:\/\/doi.org\/10.1017\/s0950268804003486","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,19]]}}}